1. 68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit
- Author
-
Ka Kit Wong, Daniel J. Wale, Eric Liao, Noah Lybik, and Benjamin L. Viglianti
- Subjects
Adenoma ,Male ,medicine.medical_specialty ,Pituitary macroadenoma ,Pet ct imaging ,Octreotide ,Treatment failure ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,Positron Emission Tomography Computed Tomography ,Organometallic Compounds ,medicine ,Humans ,Pituitary Neoplasms ,Radiology, Nuclear Medicine and imaging ,Treatment Failure ,Positron Emission Tomography-Computed Tomography ,Somatostatin receptor ,business.industry ,Treatment options ,General Medicine ,Middle Aged ,030220 oncology & carcinogenesis ,Radiology ,68Ga-DOTATATE ,business ,Orbit - Abstract
In addition to gastroenteropancreatic neuroendocrine neoplasms, a wide variety of tumors express somatostatin receptors. Somatostatin receptor imaging, heavily utilized in neuroendocrine oncology, may also have utility in the diagnosis of other neoplasms and raises the possibility of potential therapeutic options. We describe the case of a 60-year-old man who underwent 68Ga-DOTATATE PET/CT, demonstrating an avid invasive pituitary macroadenoma. This mass was persistent and refractory despite traditional treatment options. Because of the avidity, 177Lu-DOTATATE therapy was offered, although not ultimately performed, demonstrating a potential treatment for challenging cases utilizing the principles of theranostics.
- Published
- 2021
- Full Text
- View/download PDF